CN108939234B - Medicine slow-release trachea cannula - Google Patents

Medicine slow-release trachea cannula Download PDF

Info

Publication number
CN108939234B
CN108939234B CN201810488437.2A CN201810488437A CN108939234B CN 108939234 B CN108939234 B CN 108939234B CN 201810488437 A CN201810488437 A CN 201810488437A CN 108939234 B CN108939234 B CN 108939234B
Authority
CN
China
Prior art keywords
absorbent resin
powder
release
super absorbent
filter screen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810488437.2A
Other languages
Chinese (zh)
Other versions
CN108939234A (en
Inventor
董亚辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanyang Second General Hospital
Original Assignee
Nanyang Second General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanyang Second General Hospital filed Critical Nanyang Second General Hospital
Priority to CN201810488437.2A priority Critical patent/CN108939234B/en
Publication of CN108939234A publication Critical patent/CN108939234A/en
Application granted granted Critical
Publication of CN108939234B publication Critical patent/CN108939234B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A61M16/0402—Special features for tracheal tubes not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A61M16/0434—Cuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0205—Materials having antiseptic or antimicrobial properties, e.g. silver compounds, rubber with sterilising agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1025—Respiratory system
    • A61M2210/1032—Trachea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Anesthesiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a drug slow-release tracheal cannula, which comprises a body, an external interface, an air bag, a slow-release bag and an inflation inlet, wherein the body is provided with the external interface; the slow release capsule is arranged on the outer wall of the air bag, and high water absorption resin powder and anesthetic powder are filled in the slow release capsule; the slow release capsule comprises an emulsion film and a filter screen; the filter screen is a micron filter screen; the super absorbent resin powder is sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin powder, and the anesthetic powder is lidocaine hydrochloride powder. The drug-loaded micelle is formed by the super absorbent resin, so that the drug-loaded micelle is soft in texture and stable in slow release, and the anesthetic can directly reach airway mucous membranes, thereby avoiding causing airway discomfort or intubation stress reaction.

Description

Medicine slow-release trachea cannula
Technical Field
The invention relates to the technical field of medical consumables, in particular to a drug sustained-release tracheal cannula.
Background
The technology of placing a special endotracheal tube into the trachea through the glottis is called trachea intubation, and the technology can provide optimal conditions for smooth air passage, ventilation and oxygen supply, respiratory tract suction, prevention of aspiration and the like. During general anesthesia, patients with difficult-to-ensure smooth respiratory tract such as intracranial operation, thoracotomy operation, general anesthesia operation requiring special body positions such as prone position or sitting position and the like; for example, neck tumor oppresses trachea, jaw, face, neck, five sense organs and other general anesthesia major operations, and extremely obese patients; for general anesthetics to significantly inhibit respiration or for those applying muscle relaxants, intubation should be done inside the trachea. The endotracheal intubation plays an important role in the rescue of critical patients, and mechanical ventilation is needed for respiratory failure, and the endotracheal intubation is needed for cardiopulmonary resuscitation, drug poisoning and severe asphyxia of newborns.
The trachea cannula can bring serious discomfort, and the thick trachea cannula can cause discomfort, distending pain and blockage of the patient population, the nose, the pharynx and the throat after being inserted into the air passage; patients who are intubated through the oral trachea can not close the mouth and feel dry mouth, and can feel distending pain in the oral cavity and even cause damage to teeth and oral mucosa. The tracheal cannula can also cause a series of adverse reactions of an organism, namely stress reaction syndrome of the tracheal cannula, which is called tracheal cannula stress reaction for short. The trachea cannula stimulates the larynx and the inner wall of the trachea to sense an effector, can activate a body sympathetic and adrenergic system, a renin, angiotensin and aldosterone system, and then quickly promotes the release of catecholamines in high concentration in the body and acts on a target organ and a receptor thereof, thereby causing the reflex heart rate of the body to be increased, the blood pressure to be increased, even arrhythmia and the like.
The patent of publication No. CN205994836U discloses a slow-release analgesic trachea cannula, which comprises a cannula tube body, the outer surface of the cannula tube body is provided with an air bag at a position close to the front end, the outer surfaces of the cannula tube body and the air bag are coated with a slow-release analgesic coating, the cavity of the air bag is connected with an inflation tube through an inflation cavity, the inflation tube is connected with an inflation connector, the tail end of the cannula tube body is connected with an oxygen supply connector, and the outer surface of the cannula tube body is provided with scale marks.
The patent publication No. CN2710669 discloses a trachea cannula, which comprises a tube body, an air bag and an air valve, wherein the tube body is bent, one end of the tube body is connected with a respirator, the other end of the tube body is an insertion end, and the surface of the tube body is provided with scales at the end connected with the respirator in a deviation way; the gasbag is located and inserts end one side and the cladding outside the pipe near, and the gasbag both ends are connected with body gas tight, has seted up the air flue in the body wall, and air flue one end opening is in the gasbag, and the other end passes through capillary and links to each other with the gas valve, has seted up the anesthesia passageway in addition in the body wall, and anesthesia passageway one end is sealed, and the other end is drawn forth by the capillary and is linked to each other with the medicine delivery valve, and it has a plurality of medicine spraying holes to open on the anesthesia passageway.
Above-mentioned technical scheme directly sprays the narcotic in to the air flue through trachea cannula, if get into external liquid in the air flue, easily causes to choke crack the discomfort. Anesthetic is directly sprayed to the air passage for shallow local anesthesia, and the drug effect maintenance time is short; for a long-time major operation, repeated dosing is needed for many times, and the operation is complex. The prior art also has the technology of coating anesthetic outside the trachea cannula air bag, the medicine coating is thin, the duration time of the medicine effect is short, the medicine concentration is unstable, and the coating has the risk of falling off in the air passage.
Disclosure of Invention
In view of the above, the present invention aims to provide a drug sustained-release tracheal cannula, which eliminates discomfort and possible stress reaction caused by tracheal cannula, releases drug stably and reliably, and has low preparation cost.
In order to achieve the purpose, the invention adopts the following technical scheme: a drug sustained-release tracheal cannula comprises a body, an external interface, an air bag, a sustained-release bag and an inflation inlet; the slow release capsule is arranged on the outer wall of the air bag, and high water absorption resin powder and anesthetic powder are filled in the slow release capsule; the slow release capsule comprises an emulsion film and a filter screen; the filter screen is a micron filter screen;
the super absorbent resin powder is sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin powder, and the narcotic powder is lidocaine hydrochloride powder; the addition amount of the sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin powder is 0.09-0.14g, and the addition amount of the lidocaine hydrochloride powder is 0.3-0.36g; the aperture of the filter screen is 5-9 μm.
Further, the simulated use process of the drug sustained-release tracheal cannula comprises the following steps: wrapping the tracheal cannula in a water-containing matrix, and filling the air bag with air through an inflation inlet; the sustained-release capsule absorbs peripheral water, the super absorbent resin powder absorbs moisture and expands gradually, and the latex film is gradually supported; after the super absorbent resin powder absorbs water, high molecular cross-linked micelles are formed and filled with the slow release capsules, the anesthesia medicine is loaded by the high molecular cross-linked micelles, and the anesthesia medicine is slowly released to the peripheral water-containing matrix through the filter screen.
Further, the synthesis of the sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin takes sodium alginate and carboxymethyl cellulose as parent bodies, acrylic acid as a monomer, ammonium persulfate as an initiator and N, N' -methylene-bisacrylamide as a cross-linking agent.
The beneficial effects of the invention are:
the drug sustained-release tracheal cannula takes the high water-absorbent resin micelle as an anesthetic carrier, slowly releases anesthetic into an airway, performs shallow anesthesia on airway mucosa, has constant drug concentration, and can realize long-term stable drug release. The high water absorption resin powder has super strong hygroscopicity, the lidocaine hydrochloride also has strong hygroscopicity, and the water in the air passage can be absorbed through the filter screen; the volume of the super absorbent resin is greatly increased after water absorption, the slow release sac is expanded, and compared with the conventional air sac, the fit degree of the tracheal cannula and the airway is obviously improved; the slow release capsule is directly attached to the airway mucosa, so that the anesthetic slowly released by the micelle can directly reach the airway mucosa, and the anesthetic effect is more direct and efficient; the super absorbent resin after water absorption is soft, the sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin has excellent biocompatibility, and the airway discomfort caused by the full air bag and the injury of the tracheal cannula to the airway mucosa are greatly reduced.
As an important index of drug slow release, the drug-loading concentration directly influences the slow release pressure difference of the drug, and the aperture of the filter screen influences the slow release rate. The drug sustained-release tracheal cannula selects sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin, the addition amount of the super absorbent resin powder is 0.09-0.14g, the addition amount of the anesthetic powder is 0.3-0.36g, the aperture of a filter screen is 5-9 mu m, after multiple sustained-release experiments, the slow-release process of the anesthetic can reach 52 hours, and the concentration of the anesthetic is kept in the range of 20-22 g/L.
The drug sustained-release tracheal cannula maintains the concentration of the anesthetic in the optimal concentration range of the shallow local anesthesia, does not need to be repeatedly added, and does not cause discomfort or stress reaction of a patient due to the decrease of the concentration of the anesthetic or generate over anesthesia. After the trachea cannula finishes using, only need the air in the discharge gasbag, the slow-release gasbag is pressed close to the trachea cannula body, can easily follow and get the trachea cannula in the air flue, can not harm the air flue inner wall.
The drug slow-release tracheal cannula can be directly improved on the prior tracheal cannula, and the slow-release sac is additionally arranged on the outer wall of the air sac, so that the cost is low, and the operation is simple and convenient.
Drawings
FIG. 1 is a schematic structural view of a drug sustained-release tracheal cannula of the invention;
FIG. 2 is an enlarged view of a portion A of the drug-eluting endotracheal tube of the present invention shown in FIG. 1 in an unused state;
FIG. 3 is a partially enlarged view of the portion A of FIG. 1 showing the use state of the drug sustained-release endotracheal tube of the present invention;
FIG. 4 is a graph showing the sustained release concentration of the drug sustained release endotracheal tube of example 3 of the present invention;
FIG. 5 is a graph of sustained release concentration of example 4 of the drug sustained release endotracheal tube of the present invention;
FIG. 6 is a graph showing sustained release concentration of the drug sustained release endotracheal tube of example 5 of the present invention.
Detailed Description
The following are specific examples of the present invention and further describe the technical solutions of the present invention, but the present invention is not limited to these examples.
Example 1
A drug sustained-release tracheal cannula comprises a body 1, an external interface 2, an air bag 3, a sustained-release bag 4 and an inflation inlet 5. The slow release capsule 4 is arranged on the outer wall of the air bag 3. The slow release capsule 4 is filled with super absorbent resin powder and narcotic powder, and the slow release capsule 4 comprises an emulsion film 42 and a filter screen 41; the screen 41 is a micron screen.
The super absorbent resin powder is sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin powder, and the anesthetic powder is lidocaine hydrochloride powder.
The simulated use process of the drug sustained-release tracheal cannula comprises the following steps: the tracheal cannula is wrapped in the water-containing matrix, and as shown in figure 2, the air sac 3 is filled with air through the inflation inlet 5; the sustained-release capsule 4 absorbs the peripheral water, the super absorbent resin powder absorbs moisture and expands gradually, and the latex film is gradually supported; as shown in figure 3, after the super absorbent resin powder absorbs water, high molecular cross-linked micelles are formed and are filled in the slow release capsule 4, the high molecular cross-linked micelles carry the anesthetic, and the anesthetic is slowly released to the surrounding water-containing matrix through the filter screen.
Example 2
The present embodiment is different from embodiment 1 in that: the aperture of the filter screen is 5 μm. The inner edge of the latex film 42 is adhered to the outer wall of the air bag 3, and the filter screen 41 is adhered or pressed on the outer edge of the latex film 42. The filter screen can prevent the medicine mixed powder and the cross-linked water-absorbent resin from leaking, can ensure that the super-absorbent resin powder absorbs moisture quickly, and can effectively control the slow release rate and support the stable release of the anesthetic.
Example 3
The present embodiment is different from embodiment 1 in that: the pore size of the filter screen is 7 μm.
Example 4
The present embodiment is different from embodiment 1 in that: the pore size of the filter screen is 9 μm.
Selecting tracheal intubation tubes with filter screens of 5 microns, 7 microns and 9 microns in aperture respectively, placing the inflated tracheal intubation tubes into PBS buffer solution simulated body fluid, oscillating at the constant temperature of 37 ℃, completing expansion of the sustained-release capsule 4 within 8min, taking out the sustained-release solution between two halide wafers after 1h, carrying out infrared spectrum detection and analysis, and observing a stretching vibration absorption peak of carboxyl in an infrared spectrogram, thereby proving that the macromolecular cross-linked water-absorbent resin does not leak to the outer side of the sustained-release capsule 4.
Example 5
The present embodiment is different from embodiment 2 in that: the addition amount of the sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin powder is 0.09g, and the addition amount of the lidocaine hydrochloride powder is 0.3g. Placing the inflated trachea cannula into a certain amount of PBS buffer solution simulated body fluid, oscillating at constant temperature of 37 ℃, starting to measure the concentration of lidocaine hydrochloride in the buffer solution after 1 hour, taking out 2ml of sustained-release solution to be measured each time, and measuring once per hour by adopting a visible-ultraviolet spectrophotometry; meanwhile, 2ml of blank PBS buffer solution is supplemented into the simulated body fluid to simulate the consumption and loss of narcotics in the airway. FIG. 4 is a graph showing the concentration of the anesthetic released by the drug of this example.
Example 6
The present embodiment is different from embodiment 2 in that: the addition amount of the sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin powder is 0.12g, and the addition amount of the lidocaine hydrochloride powder is 0.33g. Placing the inflated tracheal cannula into a certain amount of PBS buffer solution simulated body fluid, oscillating at constant temperature of 37 ℃, starting to measure the concentration of lidocaine hydrochloride in the buffer solution after 1 hour, taking out 2ml of sustained-release solution each time for testing, and measuring once per hour by adopting a visible-ultraviolet spectrophotometry; meanwhile, 2ml of blank PBS buffer solution is supplemented into the simulated body fluid to simulate the consumption and loss of narcotics in the airway. FIG. 5 is a graph showing the concentration of the anesthetic released by the drug of this example.
Example 7
The present embodiment is different from embodiment 2 in that: the addition amount of the sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin powder is 0.14g, and the addition amount of the lidocaine hydrochloride powder is 0.36g. Placing the inflated trachea cannula into a certain amount of PBS buffer solution simulated body fluid, oscillating at constant temperature of 37 ℃, starting to measure the concentration of lidocaine hydrochloride in the buffer solution after 1 hour, taking out 2ml of sustained-release solution to be measured each time, and measuring once per hour by adopting a visible-ultraviolet spectrophotometry; meanwhile, 2ml of blank PBS buffer solution is supplemented into the simulated body fluid to simulate the consumption and loss of narcotics in the air passages. FIG. 6 is a graph showing the concentration of the anesthetic released by the drug of this example.
Example 8
The present embodiment is different from embodiment 2 in that: the synthesis of the sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin takes sodium alginate and carboxymethyl cellulose as matrixes, acrylic acid as a monomer, ammonium persulfate as an initiator and N, N' -methylene-bis-acrylamide as a cross-linking agent. The preparation process of the crosslinking polymerization of the super absorbent resin is prior art in the field, and refer to patent CN105348444A, which is not described here.
Finally, the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting, and other modifications or equivalent substitutions made by the technical solutions of the present invention by those of ordinary skill in the art should be covered within the scope of the claims of the present invention as long as they do not depart from the spirit and scope of the technical solutions of the present invention.

Claims (1)

1. A drug slow-release tracheal cannula is characterized by comprising a body, an external interface, an air bag, a slow-release bag and an inflation inlet; the slow release capsule is arranged on the outer wall of the air bag, and high water absorption resin powder and anesthetic powder are filled in the slow release capsule; the slow release capsule comprises a latex film and a filter screen, wherein the inner edge of the latex film is adhered to the outer wall of the air bag, and the filter screen is adhered to or pressed on the outer edge of the latex film; the filter screen is a micron filter screen;
the super absorbent resin powder is sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin powder, and the narcotic powder is lidocaine hydrochloride powder; the addition amount of the sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin powder is 0.09-0.14g, and the addition amount of the lidocaine hydrochloride powder is 0.3-0.36g; the aperture of the filter screen is 5-9 μm;
the simulated use process of the drug sustained-release tracheal cannula comprises the following steps: wrapping the tracheal cannula in a water-containing matrix, and filling the air bag with gas through an inflation inlet; the sustained-release capsule absorbs the peripheral water, the super absorbent resin powder absorbs moisture and expands gradually, and the latex film is gradually supported; after the super absorbent resin powder absorbs water, high molecular cross-linked micelles are formed and filled with the slow release capsules, the high molecular cross-linked micelles carry the anesthetic, and the anesthetic is slowly released to the surrounding water-containing matrix through the filter screen;
the synthesis of the sodium alginate/carboxymethyl cellulose/acrylic acid super absorbent resin takes sodium alginate and carboxymethyl cellulose as matrixes, acrylic acid as a monomer, ammonium persulfate as an initiator and N, N' -methylene-bisacrylamide as a cross-linking agent.
CN201810488437.2A 2018-05-21 2018-05-21 Medicine slow-release trachea cannula Active CN108939234B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810488437.2A CN108939234B (en) 2018-05-21 2018-05-21 Medicine slow-release trachea cannula

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810488437.2A CN108939234B (en) 2018-05-21 2018-05-21 Medicine slow-release trachea cannula

Publications (2)

Publication Number Publication Date
CN108939234A CN108939234A (en) 2018-12-07
CN108939234B true CN108939234B (en) 2023-01-31

Family

ID=64499285

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810488437.2A Active CN108939234B (en) 2018-05-21 2018-05-21 Medicine slow-release trachea cannula

Country Status (1)

Country Link
CN (1) CN108939234B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4417576A (en) * 1982-02-25 1983-11-29 Baran Ostap E Double-wall surgical cuff
CN2664694Y (en) * 2003-05-22 2004-12-22 濮阳市协和医疗器械制品有限公司 Conduit for continuous surface anesthesia for laryngopharynx and trachea inner mucous membrane
US7410480B2 (en) * 2004-04-21 2008-08-12 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
CN105348444B (en) * 2015-12-09 2018-08-17 中国-阿拉伯化肥有限公司 A kind of super absorbent resin and preparation method thereof

Also Published As

Publication number Publication date
CN108939234A (en) 2018-12-07

Similar Documents

Publication Publication Date Title
Guyton et al. High-volume, low-pressure cuffs: are they always low pressure?
Lee et al. Comparison of the single-use LMA supreme with the reusable ProSeal LMA for anaesthesia in gynaecological laparoscopic surgery
US9533070B2 (en) Therapeutic agent for pulmonary emphysema
CN208809293U (en) A kind of gastroenterology esophagus medicator
JP2018149342A (en) Nasal pulsatile oxygenation and ventilation airway apparatus
CN108939234B (en) Medicine slow-release trachea cannula
CN105079945B (en) A kind of alimentary canal double-layer seal formula balloon tube
US9669182B2 (en) Nasal jet airway
US8808276B2 (en) Adaptive dispensation in a digestive tract
CN108671352A (en) A kind of trachea cannula
CN208436195U (en) A kind of first aid two-chamber double cuff larynx snorkel
CN208002843U (en) A kind of compliance Gastroesophageal hemostasis device
Kim The tracheal tube cuff pressure stabilizer and its clinical evaluation
CN109701130A (en) A kind of first aid two-chamber double cuff larynx snorkel
JP6746592B2 (en) Bronchial sealant delivery method and system
CN206822615U (en) Medical aid
CN214912137U (en) Tracheal catheter for department of respiration
CN111714744A (en) Non-inflatable cuff and endotracheal intubation
CN215383884U (en) Ventilating oxygen tube for bronchoscopy
CN213347313U (en) Gel type laryngeal mask structure
CN211410569U (en) Double-sac intubation tube
Shanthini A Comparative study of Supraglottic Airway Devices Classic LMA, Proseal LMA, Blockbuster LMA in Adult Patients Undergoing Short Surgical Procedures under General Anaesthesia
CN219071640U (en) Powder fog agent air suction flow monitoring and auxiliary device
Crowley et al. BREATHS: A Novel Endotracheal Tube Design to Decrease the Incidence of Tracheal Lesions
CN212066793U (en) Appearance is aerifyd to accurate accuse pressure volume of gasbag

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant